Barbexaclone

Summary

Barbexaclone (CHEMBL3833301) is an approved small molecule (ATC N03AA04); indicated across 1 condition including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AA04
• Indications: 1 condition
• Chemistry: 387.5 Da · C22H33N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833301
Name	Barbexaclone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9977518
ATC	N03AA04
Molecular formula	C22H33N3O3
Molecular weight	387.5
InChIKey	MJCBWPMBFCUHBP-UHFFFAOYSA-N

SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2.CC(CC1CCCCC1)NC

IUPAC name: 1-cyclohexyl-N-methylpropan-2-amine;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione

Also known as: Barbexaclona, Barbexaclone, Maliasin, BARBEXACLONE

Patent coverage: 7 distinct patent families (10 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).